| Description | AVE-0118 is a potassium channel blocker and suppresses persistent atrial fibrillation. |
| Synonyms | AVE 0118, AVE0118 |
| molecular weight | 479.57 |
| Molecular formula | C30H29N3O3 |
| CAS | 498577-53-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (114.69 mM) |
| References | 1. Burashnikov A, et al. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol. 2012 Jun;59(6):539-46. 2. Wirth KJ, Steinmeyer K, Ruetten H. Sensitization of upper airway mechanoreceptors as a new pharmacologic principle to treat obstructive sleep apnea: investigations with AVE0118 in anesthetized pigs. Sleep. 2013 May 1;36(5):699-708. 3. Christ T, et al. Pathology-specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation. Br J Pharmacol. 2008 Aug;154(8):1619-30. 4. Schneider HJ, et al. Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure. Naunyn Schmiedebergs Arch Pharmacol. 2009 Mar;379(3):225-32. |